Novartis | NOVN - Cash And Equivalent


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Novartis

Novartis reported $12B in Cash and Equivalent for its fiscal quarter ending in March of 2023.


Cash And Equivalent Change
Alcon AG ALC:SW USD 889M 91M
Almirall SA ALM:SM EUR 248.38M 24.12M
Amgen AMGN:US USD 31.56B 22.26B
Artemis Alpha ATS:LN GBP 978K 1.41M
AstraZeneca AZN:LN USD 6.23B 66M
Bayer BAYN:GR EUR 4.85B 317M
Biogen BIIB:US USD 2.9B 521.1M
Bristol-Myers Squibb BMY:US USD 9B 128M
Eli Lilly LLY:US USD 3.55B 1.48B
Fresenius FRE:GR EUR 2.32B 1.75B
Galapagos GLPG:NA EUR 124.14M 383.98M
Genmab GEN:DC DKK 12.29B 2.4B
Gilead Sciences GILD:US USD 7.2B 430M
GlaxoSmithKline GSK:LN GBP 2.89B 833M
Hikma Pharmaceutical HIK:LN USD 1000K 22M
J&J JNJ:US USD 3.36B 2B
Lonza Group LONN:SW CHF 1.34B 187M
Merck MRK:GR EUR 1.58B 270M
Novartis NOVN:VX USD 12B 4.48B
Novartis NVS:US USD 12B 4.48B
Orion ORNBV:FH EUR 99.8M 232.8M
Recordati REC:IM EUR 231.29M 53.44M
Regeneron Pharmaceuticals REGN:US USD 3.92B 810.4M
Roche Holding ROG:VX CHF 4.99B 676M
UCB UCB:BB EUR 899M 384M